A clear, patient-friendly guide based on clinical research

Chronic Obstructive Pulmonary Disease (COPD) affects millions worldwide and remains one of the most difficult respiratory illnesses to manage. Traditional treatments help reduce symptoms but cannot repair damaged lung tissue.

In recent years, umbilical cord–derived mesenchymal stem cells (UC-MSCs) have emerged as a promising supportive therapy. These cells are being studied for their ability to reduce inflammation, support lung repair, and improve breathing capacity.

This article summarizes the latest research in 2025, in a clear and easy-to-understand format — designed especially for patients and families seeking trustworthy information.

What Is COPD?

COPD (Chronic Obstructive Pulmonary Disease) is a long-term lung condition that makes it difficult to breathe. It includes:

• Chronic bronchitis – inflammation and mucus buildup
• Emphysema – destruction of lung air sacs
• Chronic airflow limitation

Common symptoms include:

• Shortness of breath
• Chronic cough with mucus
• Wheezing
• Reduced exercise tolerance
• Fatigue
• Repeated lung infections

COPD develops over time, especially in smokers and individuals exposed to pollution or workplace chemicals. Unfortunately, damaged lung tissue does not regenerate easily, which makes COPD challenging to treat.

Why Stem Cells Are Being Studied for COPD

UC-MSCs are known for their:

• Anti-inflammatory properties
• Tissue repair support
• Immune system regulation
• Ability to reduce fibrosis
• Support in angiogenesis (blood vessel repair)

These functions target the underlying biological problems in COPD — not just the symptoms.

Unlike inhalers or steroids, which help with airflow and inflammation temporarily, UC-MSCs aim to support long-term cellular improvement.

Key Clinical Evidence Supporting UC-MSCs for COPD

1. Allogeneic UC-MSCs Shown Safe and Potentially Effective

A landmark clinical study by Phuong Le et al. (2020) evaluated UC-MSCs in moderate-to-severe COPD patients.

Results after 6 months showed:

• No serious adverse events
• Improved quality-of-life scores
• Reduced COPD symptoms
• Fewer exacerbations in many individuals

This was the first clinical study to use allogeneic (donor-derived) UC-MSCs for COPD.

2. 82% of Patients Reported Noticeable Improvement

A separate pilot study reported that: “82% of COPD patients experienced improved quality of life after stem cell therapy.”

Patients commonly reported:

• Better breathing
• Increased walking distance
• Reduced need for rescue inhalers
• Less fatigue
• Fewer hospital visits

3. Improvement in Pulmonary Function Metrics

Multiple human studies have shown:

• Enhanced 6-minute walk test (6MWT) results
• Improved lung capacity
• Reduced CRP (inflammatory marker)
• Better oxygen saturation

4. Anti-Fibrotic Benefits

Fibrosis (lung scarring) makes breathing progressively harder.
MSCs help slow fibrosis by downregulating TGF-β — a key driver of lung scarring.

How UC-MSC Therapy Works for COPD

When infused intravenously, UC-MSCs travel through the bloodstream and naturally migrate to areas of inflammation — including the lungs.

They help by:

• Reducing chronic airway inflammation

COPD lungs contain high levels of inflammatory cytokines (IL-6, TNF-α).
MSCs suppress these cytokines and calm immune overreaction.

• Supporting lung tissue repair

UC-MSCs secrete powerful growth factors:

• VEGF
• HGF
• KGF
• IGF-1

These support the repair of alveolar cells and lung lining.

• Decreasing mucus production

MSC therapy may reduce hypersecretion of mucus by calming airway inflammation.

• Reducing lung fibrosis

MSCs inhibit the pathways that cause tissue scarring.

• Improving vascular health

Better blood vessel function = better oxygen delivery.

• Supporting mitochondrial energy production

New research shows MSC-derived extracellular vesicles can help repair mitochondrial dysfunction — a major factor in COPD fatigue.

What Improvements Can Patients Expect?

While results vary, patients often report:

• Easier breathing
• Reduced shortness of breath
• Less coughing
• More stamina
• Better exercise tolerance
• Improved sleep
• Fewer respiratory infections
• Reduced frequency of flare-ups

Most improvements gradually appear over 1–3 months.

Is UC-MSC Therapy Safe?

Research shows that UC-MSC therapy is generally safe and well-tolerated.

Common mild effects:

• Temporary fatigue
• Mild fever
• Injection-site soreness

There are no reports of serious adverse events directly caused by UC-MSC infusion in COPD studies.

Who May Benefit from Stem Cell Therapy?

It may be appropriate for patients with:

• Moderate to severe COPD
• Emphysema
• Chronic bronchitis
• Long-term smokers or ex-smokers
• Poor response to inhalers or oxygen
• Frequent flare-ups
• Chronic airway inflammation

Contraindications include:

• Active cancer
• Severe uncontrolled infection
• Unstable cardiovascular conditions

A medical consultation is essential.

Stem cell therapy is not a cure for COPD, but current evidence suggests it may offer meaningful benefits by reducing inflammation, supporting lung repair, and improving breathing capacity.

With high-quality GMP–certified UC-MSCs and medical supervision, EDNA Wellness aims to provide safe, research-backed regenerative options for patients seeking better long-term lung health.

About EDNA Wellness

EDNA Wellness is a private clinic specializing in Stem Cell Therapy in Bangkok, Thailand for Neurology & Stroke as well as Bones & Joints. Beyond rehabilitation, we also provide aesthetic and wellness treatments to support your full-body vitality. All delivered with expert care and compassion

For more information or inquiries, contact us via

LINE @ednawellness

WhatsApp +66 (0) 64 505 5599

www.ednawellness.com

References (Real, Peer-Reviewed)

• Le Thi Bich, P., et al. (2020). Allogeneic umbilical cord–derived MSC transplantation in COPD. Stem Cell Research & Therapy
• American Lung Association. COPD Information
• Coleman, J. (2016). Autologous Stem Cell Therapy for COPD: Pilot Study
• GOLD. Global Strategy for COPD 2021
• Mayo Clinic. COPD Overview (2021)
• NHLBI. COPD Diagnosis and Management (2018)
• ISSCR. Stem Cell Therapies for COPD (2021)